COMMUNIQUÉS West-GlobeNewswire

Nicox : Participation à des conférences d’industrie pharmaceutique et financière
29/04/2019
Pour Information Nicox : Participation à des conférences d’industrie pharmaceutique et financière 29 Avril Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX, éligible PEA-PME), une société [...]
Santhera Reports Strong Top-line Growth for 2018 and the Successful Expansion of its Rare Disease Pipeline
29/04/2019
Pratteln, Switzerland, April 29, 2019 - Santhera Pharmaceuticals (SIX: SANN) announces the Group's audited financial results for 2018. The Company reports a 38% increase in net revenues year-on-year to CHF 31.7 million [...]
Bone Therapeutics SA: Information on the total number of voting rights and shares
29/04/2019
Regulated information Gosselies, Belgium, 29 April 2019, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone [...]
Bone Therapeutics SA : Information relative au nombre total de droits de vote et d’actions
29/04/2019
Information réglementée Gosselies, Belgique, le 29 avril 2019, 07h00 CEST - BONE THERAPEUTICS (code Euronext Bruxelles et Paris : BOTHE), société de thérapie cellulaire osseuse qui répond à d’importants besoins médicaux [...]
Addex to Announce 2018 Full Year Audited Results on April 30, 2019
29/04/2019
Geneva, Switzerland, April 29, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that it will report its full-year audited [...]
ObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVF
29/04/2019
Geneva, Switzerland and Boston, MA – April 29 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious [...]
Philips delivers Q1 sales of EUR 4.2 billion, with 2% comparable sales growth; income from continuing operations increased to EUR 171 million and Adjusted EBITA margin improved to 8.8%
29/04/2019
April 29, 2019 First-quarter highlights • Sales in the quarter amounted to EUR 4.2 billion, with 2% comparable sales growth • Comparable order intake increased 2% • Income from continuing operations increased to EUR 171 [...]
Sanofi: FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization
27/04/2019
FDA approves Praluent ® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization Praluent is the first PCSK9 inhibitor that has shown a meaningful reduction in death from any cause [...]
Sanofi : La FDA approuve Praluent® (alirocumab) dans la prévention du risque d'infarctus du myocarde, d'accident vasculaire cérébral et d'angor instable nécessitant une hospitalisation
27/04/2019
La FDA approuve Praluent ® (alirocumab) dans la prévention du risque d'infarctus du myocarde, d'accident vasculaire cérébral et d'angor instable nécessitant une hospitalisation Praluent est le premier inhibiteur de [...]
Aurora Spine Corporation Announces 2018 Year End Results
26/04/2019
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES CARLSBAD, Calif., April 26, 2019 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) announces [...]
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
26/04/2019
BOTHELL, Wash., April 26, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today [...]
Alder BioPharmaceuticals® to Host Conference Call to Discuss First Quarter 2019 Financial and Operating Results
26/04/2019
BOTHELL, Wash., April 26, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today [...]
ZynquistaTM now approved in the European Union for treatment of adults with type 1 diabetes
26/04/2019
Zynquista TM now approved in the European Union for treatment of adults with type 1 diabetes PARIS and THE WOODLANDS, TX - April 26, 2019 - The European Commission has granted marketing authorization for Zynquista (TM [...]
ZynquistaTM désormais approuvé dans l'Union européenne pour le traitement du diabète de type 1 de l'adulte
26/04/2019
Zynquista TM désormais approuvé dans l'Union européenne pour le traitement du diabète de type 1 de l'adulte Paris et The Woodlands (Texas) - Le 26 avril 2019 - La Commission européenne a délivré une autorisation de mise [...]
Zynquista™ now Approved in the European Union for Treatment of Adults With Type 1 Diabetes
26/04/2019
PARIS and THE WOODLANDS, Texas, April 26, 2019 (GLOBE NEWSWIRE) -- The European Commission has granted marketing authorization for Zynquista™ (sotagliflozin)*, developed by Sanofi and Lexicon (Nasdaq: LXRX). Zynquista [...]
Avricore Health Provides Corporate Update
26/04/2019
Vancouver, April 26, 2019 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSXV: AVCR) (“Avricore”) announced today the resignation of Ms. Leanne Ratzlaff as Corporate Secretary effective immediately. Due to the growth in [...]
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
26/04/2019
CHICAGO, April 26, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable [...]
CohBar to Announce 2019 First Quarter Financial Results and Provide Business Update on May 7, 2019
26/04/2019
Company to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., April 26, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based [...]
Genkyotex : mise à disposition du document de référence 2018
26/04/2019
ARCHAMPS, France, 26 avr. 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris et Euronext Brussels : FR0013399474 – GKTX), la société biopharmaceutique leader des thérapies NOX, annonce aujourd’hui que son document de [...]

Pages